Targeted CMV prophylaxis with valganciclovir viable

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1289, 2001-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted CMV prophylaxis with valganciclovir viable

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 314, 2001-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Valganciclovir proves its value in CMV prevention

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 608, 2010-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Valganciclovir: once-daily alternative to ganciclovir for CMV

By  

Inpharma, Vol. 1, Iss. 1365, 2002-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Valganciclovir prevents CMV infection in lung transplantation

By  

Inpharma, Vol. 1, Iss. 1465, 2004-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients

By Åsberg Anders   Rollag Halvor   Hartmann Anders  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1159-1166

Informa Healthcare

Access to resources Recommend Favorite